Liquid biopsies provide hope for quicker and more accurate early-stage cancer detection across a wider range of cancer types with a simple blood test. Using current standard of care, only about 25% of cancers are detected via screening.1 The remaining 75% are detected when the patient is symptomatic, and most likely in a later stage of cancer.2
Largely as a result, cancer accounts for 609,000 deaths a year in the United States, making it the second leading cause of death.3 Liquid biopsies, however, provide hope.
This approach can be particularly beneficial for detecting cancers that currently do not have proven screening methods and thus require invasive tissue biopsies. In this piece, we introduce liquid biopsy technology and examine what it will take for it to become a prominent standard of care.
Biomarkers are biological molecules found in a patient’s sample that serve as medical signs to specific illnesses.4 For a long time, finding biomarkers for solid tumors was limited to tissue samples, collected via a tissue biopsy.
Tissue biopsies can be particularly challenging when a tumor is difficult to access, such as a tumor in the brain or lung. New methods, however, now allow scientists to use biomarkers in non-invasive liquid samples, like blood or urine, to detect cancer. The most studied biomarkers so far for liquid biopsy include:
The genetic information obtained from these biomarkers spans multiple uses and can aid in patient care across their diagnostic and treatment journey.
For early cancer detection, tumor-specific assays solely focus on diagnosing one type of cancer. Exact Sciences’ (EXAS) Cologuard, for example, is a Food and Drug Administration (FDA)-approved test that can help detect colon cancer via cancerous particles in stool.
Though colonoscopies remain the standard of care for colon cancer diagnosis, a liquid biopsy test such as Cologuard can help rule out colon cancer. Exact states that 84% of Cologuard patients test negative, with a 99.94% negative predictive value.10
If Cologuard patients test positive, it indicates potential signs of colon cancer and the patient should schedule a colonoscopy. Ruling out patients is valuable, particularly now, as the COVID-19 pandemic resulted in patients putting off elective procedures that resulted in a years-long backlog of colonoscopy procedures.11
Recent work in the multi-cancer early detection (MCED) space looks for a wider net of cancer-derived biomarkers. MCED tests, sometimes also referred to as pan-cancer early detection tests, simultaneously screen for and localize multiple cancers.
Meant to be used to complement with existing diagnostic options, MCEDs signal that the patient requires more in-depth examination. Illumina’s (ILMN) Grail launched the first commercially available MCED in 2021.12 The test detects 50 types of cancer with 99.5% specificity and 89% cancer signal origin accuracy.13
Overall sensitivity for the test was 51.5%, with a steady improvement in detection across cancer stages: 17% at stage I, 40% at stage II, 77% at stage III, and 90% at stage IV.14
The liquid biopsy space is still quite nascent compared to other cancer screening alternatives and firms continue to pursue improved test accuracy. Two possibilities are multi-omic and combined biomarker approaches. Omics are used to better understand the roles, relationships, and actions of different types of molecules that make up human cells.15
Combining approaches is expected to lead to increased insights gathered from a single liquid biopsy assay and improved accuracy rates. For pan-cancer tests, combined approaches could also improve the accuracy rate for detecting cancer origin.
Firms also want to provide multiple sample options for tumor-specific assays. Exact Sciences is developing a blood-based test for colon cancer that would complement its stool-based Cologuard test.16 For detection or monitoring of other cancer types, sample types like urine and saliva might be in play.
For example, urine might be an appropriate sample for detecting kidney cancer due to increased tumor shedding in the sample compared to blood.17 In instances where multiple tests come to market with different sample options, we expect adoption to be largely determined by test accuracy and patient preference.
The Centers for Disease Control and Prevention (CDC) recently found that cancer deaths decreased 27% from 2000 to 2020, given more effective and widely available cancer screening options for asymptomatic patients.18 Overwhelming evidence shows that earlier detection of colon cancer will improve patient outcomes significantly.
As a result, firms used colon cancer to validate liquid biopsy and forge a pathway towards FDA approval and reimbursement coverage for tests. Crucial questions, however, remain unanswered about how expanded use of liquid biopsy will be implemented and what clinical best practices should be followed after a positive test result.
In our view, establishing robust downstream guidelines for diagnostic and post-diagnostic care is essential to ensure increased adoption of liquid biopsies. Currently, it’s customary for specialists to perform cancer screening, if available, and diagnosis.
For example, when a patient is screened for cervical cancer, an OB-GYN most likely makes the diagnosis via a Pap test. Conversely, MCEDs, could serve as a screening aid as a part of annual blood work. Physicians will need a clear workflow, which must be built from the ground up.
Robust downstream guidelines can ensure that patients have a seamless experience with the product and aid in the medical community embracing liquid biopsy’s clinical utility. For example, the commercial strategy should include ideal patient characteristics. Illumina’s GRAIL suggests that patients with an elevated risk of cancer and those over 50 are the ideal group to benefit from such a test.19
The more late-stage clinical trial data and commercial adoption continue to validate liquid biopsy technology, the more companies enter the market. In our view, test accuracy and result comprehensibility will be the primary determinants of success for any company or test. Other factors, like reimbursement level and company reputation within the physician community, will also play important roles.
In this increasingly competitive market, firms are taking steps to differentiate themselves. Guardant Health (GH), for example, recently announced that it formed a partnership with electronic health records (EHR) firm Epic. The partnership will integrate Guardant’s portfolio of cancer tests into the Epic system. Epic is one of the two major EHR providers in the United States.20
In our view, the firms best positioned to drive test adoption will be those that have comprehensive portfolios with diagnostic options at each step along the entire cancer care continuum, from diagnosis through remission.
In addition, we believe having both tissue and liquid-based diagnostic options will help validate the benefit of this new diagnostic approach and drive long-term adoption. Breadth of portfolio will also aid firms in gaining reimbursement coverage, which will ultimately make the technology accessible to a greater patient population.
Beyond traditional points along the cancer care continuum, we anticipate that hereditary cancer testing and real-world evidence (RWE) will increasingly converge with the segments of traditional oncology diagnostics that liquid biopsy addresses:
Liquid biopsy technology has momentum as an increasingly viable early-stage cancer detection tool. We’re seeing that momentum play out as firms expand their portfolios and established life sciences companies enter the space.
Increased acquisition activity is another telltale sign of liquid biopsy’s growth potential, including Exact Sciences’ $2.15 billion acquisition of Thrive Earlier Detection, Illumina’s $8 billion re-acquisition of Grail, and Agilent’s (A) $550 million acquisition of Resolution Sciences.26, 27, 28
In our view, these developments can accelerate research in the industry and shift the oncology landscape as patients and providers begin to experience the benefits.
AGNG: The Global X Aging Population ETF seeks to invest in companies positioned to serve the world’s growing senior population through exposure to health care, pharmaceuticals, senior living facilities and other sectors that contribute to increasing lifespans and extending quality of life in advanced age.
GNOM: The Global X Genomics & Biotechnology ETF seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.
Click the fund name above to view current holdings. Holdings are subject to change. Current and future holdings are subject to risk.
Specificity: A test’s ability to correctly identify people without the disease, i.e., the true negativity rate.
Sensitivity: A test’s ability to correctly identify patients with the disease, i.e., the true positivity rate.
Extracellular Vesicles: A group of cell-derived structures involved in key biological processes. They are a part of intracellular communication, allowing cells to exchange proteins, lipids, and genetic material.29
Cancer Signal Origin: A test’s ability to currently identify the origin of the signal, i.e., what cancer type the patient has.
Omics: A field of study in biological sciences that ends with -omics, such as genomics, transcriptomics, proteomics, or metabolomics. Refers to the collective technologies used to explore the roles, relationships, and actions of molecules that make up the cells of an organism.30, 31
BRCA: BRCA1 and BRCA2 are tumor suppressor genes important to fighting cancer. A change or mutation in these genes can prevent them from working normally and might raise a patient’s risk for breast, ovarian, and/or other cancer.32
SEI Investments Distribution Co. (1 Freedom Valley Drive, Oaks, PA, 19456) is the distributor for the Global X Funds.
Investing involves risk, including the possible loss of principal. The investable universe of companies in which GNOM and AGNG may invest may be limited. GNOM invests in securities of companies engaged in Genomics, Healthcare and Biotechnology sectors. AGNG invests in securities of companies engaged in Healthcare, Pharmaceutical, Biotechnology and Medical Device sectors. These sectors can be affected by government regulations, rapid product obsolescence, intense industry competition and loss or impairment of patents or intellectual property rights. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles or from social, economic, or political instability in other nations. GNOM and AGNG are non-diversified.
Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns.
Carefully consider the funds’ investment objectives, risks, and charges and expenses. This and other information can be found in the funds’ full or summary prospectuses, which may be obtained at globalxetfs.com. Please read the prospectus carefully before investing.
Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive AG and Indxx, nor does Solactive AG and Indxx make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with Solactive AG and Indxx.
Editor's Note: The summary bullets for this article were chosen by Seeking Alpha editors.
This article was written by